RetinalGenix Technologies Valuation
| RTGN Stock | USD 3.20 0.00 0.00% |
At this time, the company appears to be overvalued. RetinalGenix Technologies holds a recent Real Value of $2.84 per share. The prevailing price of the company is $3.2. Our model determines the value of RetinalGenix Technologies from analyzing the company fundamentals such as Net Income of (2.18 M), shares owned by insiders of 66.02 %, and Return On Asset of -49.71 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors support obtaining undervalued entities and abandoning overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that RetinalGenix Technologies' price fluctuation is moderately volatile at this time. Calculation of the real value of RetinalGenix Technologies is based on 3 months time horizon. Increasing RetinalGenix Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the RetinalGenix otc stock is determined by what a typical buyer is willing to pay for full or partial control of RetinalGenix Technologies. Since RetinalGenix Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of RetinalGenix OTC Stock. However, RetinalGenix Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.2 | Real 2.84 | Hype 3.2 |
The intrinsic value of RetinalGenix Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence RetinalGenix Technologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of RetinalGenix Technologies helps investors to forecast how RetinalGenix otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of RetinalGenix Technologies more accurately as focusing exclusively on RetinalGenix Technologies' fundamentals will not take into account other important factors: RetinalGenix Technologies Total Value Analysis
RetinalGenix Technologies is at this time forecasted to have valuation of 155.49 M with market capitalization of 162.36 M, debt of 114.69 K, and cash on hands of 27. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the RetinalGenix Technologies fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
155.49 M | 162.36 M | 114.69 K | 27 |
RetinalGenix Technologies Asset Utilization
One of the ways to look at asset utilization of RetinalGenix is to check how much profit was generated for every dollar of assets it reports. RetinalGenix Technologies holds a negative application of assets of -49.71 pct., losing $0.5 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of RetinalGenix Technologies shows how discouraging it operates for each dollar spent on its assets.RetinalGenix Technologies Ownership Allocation
RetinalGenix Technologies owns a total of 17.27 Million outstanding shares. RetinalGenix Technologies holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 66.02 pct. of RetinalGenix Technologies outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.RetinalGenix Technologies Profitability Analysis
Net Loss for the year was (2.18 M) with profit before overhead, payroll, taxes, and interest of 0.About RetinalGenix Technologies Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of RetinalGenix Technologies. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of RetinalGenix Technologies based exclusively on its fundamental and basic technical indicators. By analyzing RetinalGenix Technologies's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of RetinalGenix Technologies's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of RetinalGenix Technologies. We calculate exposure to RetinalGenix Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of RetinalGenix Technologies's related companies.RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC. Retinalgenix Technologies operates under Medical Devices classification in the United States and is traded on OTC Exchange.
8 Steps to conduct RetinalGenix Technologies' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates RetinalGenix Technologies' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct RetinalGenix Technologies' valuation analysis, follow these 8 steps:- Gather financial information: Obtain RetinalGenix Technologies' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine RetinalGenix Technologies' revenue streams: Identify RetinalGenix Technologies' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research RetinalGenix Technologies' industry and market trends, including the size of the market, growth rate, and competition.
- Establish RetinalGenix Technologies' growth potential: Evaluate RetinalGenix Technologies' management, business model, and growth potential.
- Determine RetinalGenix Technologies' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate RetinalGenix Technologies' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
RetinalGenix Technologies Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 14.3 M | |
| Retained Earnings | -5.1 M |
Other Information on Investing in RetinalGenix OTC Stock
RetinalGenix Technologies financial ratios help investors to determine whether RetinalGenix OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RetinalGenix with respect to the benefits of owning RetinalGenix Technologies security.